Berberrubine chloride: Selective IMPDH2 Inhibitor for Advanced Cancer and Metabolic Research

Executive Summary: Berberrubine chloride (SKU N2089, APExBIO) is a hydrochloride salt of the natural product berberrubine, exhibiting potent, selective inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2, IC₅₀ 2.37 μM) and thioredoxin reductase (TrxR, IC₅₀ 5.0 μM) in cell-based and biochemical assays (He et al., 2023). It blocks proliferation in colorectal cancer (SW620/LS174T) and NSCLC (A549) cell lines at 10–80 μM, demonstrating >15-fold selectivity for IMPDH2 over IMPDH1 under standard in vitro conditions. In vivo, daily dosing (6.25–200 mg/kg) reduces tumor growth and serum uric acid by over 75% in preclinical models without increasing bleeding risk. The compound also modulates urate transporters (URAT1, GLUT9, OAT1/3, ABCG2), inhibits topoisomerase II, and suppresses NF-κB and JAK2/STAT3 signaling (APExBIO).

Biological Rationale

Berberrubine chloride is a metabolite of berberine, primarily isolated from Coptis chinensis, a key component in traditional Chinese medicine (He et al., 2023). IMPDH2 catalyzes the conversion of inosine 5′-monophosphate (IMP) to xanthosine 5′-monophosphate (XMP), a critical step in de novo guanine nucleotide biosynthesis. IMPDH2, but not IMPDH1, is highly upregulated in colorectal cancer (CRC) and correlates with poor prognosis. Selective inhibition of IMPDH2 disrupts nucleotide pools required for tumor cell proliferation while sparing normal leukocytes, where IMPDH1 predominates. Additional targets such as TrxR and urate transporters expand the compound's utility in cancer, inflammation, and metabolic disease models. Berberrubine chloride is insoluble in water or ethanol but dissolves in DMSO at ≥6.42 mg/mL with gentle warming and sonication (APExBIO).

Mechanism of Action of Berberrubine chloride

• IMPDH2 Inhibition: Berberrubine chloride selectively inhibits IMPDH2 (IC₅₀ 2.37 μM), with >15-fold selectivity against IMPDH1. This impairs guanine nucleotide synthesis, stalling the cell cycle in cancer cells (He et al., 2023).
• TrxR Targeting: It covalently binds TrxR at the Sec498 residue (IC₅₀ 5.0 μM), interfering with redox regulation in cancer and inflammatory cells.
• VKOR and GGCX Inhibition: Inhibits vitamin K epoxide reductase and γ-glutamyl carboxylase, relevant for thrombosis and tumor biology.
• GSTM2 Activation: Activates glutathione S-transferase Mu2 (GSTM2) through SP1 transcription factor upregulation and DNA demethylation.
• NF-κB/JAK2/STAT3 Suppression: Blocks nuclear translocation of NF-κB and the JAK2/STAT3 signaling pathway, both critical for inflammatory and tumorigenic responses.
• Urate Transporter Modulation: Downregulates URAT1/GLUT9 and upregulates OAT1/3/ABCG2, reducing systemic uric acid levels.
• Topoisomerase II Inhibition: Prevents DNA cleavage and repair, contributing to anti-proliferative effects.

Evidence & Benchmarks

• Berberrubine chloride inhibits IMPDH2 with an IC₅₀ of 2.37 μM, showing >15-fold selectivity over IMPDH1 (He et al., 2023).
• In CRC cell lines (SW620, LS174T), berberrubine chloride impairs cell growth in a dose-dependent manner (10–80 μM, 37°C, DMEM medium) (He et al., 2023).
• Oral administration reduces tumor volume and weight in CRC xenograft mouse models at 20–100 mg/kg/day (He et al., 2023).
• Serum uric acid levels decrease by over 75% in hyperuricemic mice treated with 50–200 mg/kg/day, with no observed increase in bleeding (APExBIO).
• Enhances cisplatin chemosensitivity in NSCLC A549 cells at 20–50 μM (APExBIO, 2024).
• IC₅₀ for TrxR inhibition is 5.0 μM at standard in vitro conditions (pH 7.4, 25°C, recombinant enzyme) (OctocryleneAPI, 2024).

Applications, Limits & Misconceptions

Berberrubine chloride is intended for research use only. Its primary applications include:

• Colorectal cancer research (cellular and animal models)
• Non-small cell lung cancer (NSCLC) resistance and chemosensitization workflows
• Hyperuricemia and urate transporter studies
• Anti-inflammatory and anti-thrombosis mechanisms
• Mechanistic evaluation of IMPDH2 and TrxR selective inhibition

For a broader mechanistic perspective, see this review, which expands on GSTM2 and JAK2/STAT3 modulation; this article sharpens the focus on direct IMPDH2 selectivity and translational benchmarks. Similarly, BCA-Protein.com summarizes multi-target effects, while this article provides direct evidence quantification and protocols. For translational strategy guidance, Afobazolesyn.com discusses workflow integration, which is updated here with recent data.

Common Pitfalls or Misconceptions

• Berberrubine chloride is not suitable for clinical or diagnostic use; it is for research only.
• Insoluble in water or ethanol—proper DMSO solubilization (≥6.42 mg/mL) and sonication are required.
• Not a general IMPDH inhibitor—selectivity is for IMPDH2, not IMPDH1.
• In vivo dosing must be tailored to the disease model and species; direct clinical translation of animal doses is not valid.
• Not effective against all tumor types or cell lines—activity is best established in CRC and NSCLC models.

Workflow Integration & Parameters

• Compound Handling: Store solid berberrubine chloride at –20°C, protected from light and moisture.
• Solubilization: Dissolve in DMSO at ≥6.42 mg/mL using gentle warming and ultrasonic treatment.
• In Vitro: Use at 10–80 μM in CRC (SW620, LS174T), 20–50 μM in NSCLC (A549), 0.2–25 μM in ARPE-19, and 50 μM in BFTC 905 cells.
• In Vivo: Typical dosing ranges from 6.25 to 200 mg/kg/day (mouse/rat), depending on the disease indication. Use vehicle controls and perform dose-response validation.
• Readouts: Assess cell proliferation, apoptosis, uric acid levels, and pathway-specific markers (e.g., p-STAT3, nuclear NF-κB).
• Controls: Compare with non-selective IMPDH inhibitors (e.g., mycophenolic acid) and untreated controls.

Conclusion & Outlook

Berberrubine chloride (APExBIO, N2089) is a robust, selective research tool for dissecting IMPDH2-dependent tumor proliferation and metabolic dysregulation. Its unique multi-target profile, DMSO solubility, and established in vitro/in vivo benchmarks enable advanced mechanistic and translational research in cancer, inflammation, and metabolic diseases. For up-to-date protocols and sourcing, visit the Berberrubine chloride product page. Ongoing studies are expanding its application to drug-resistance models and combinatorial therapies. Researchers should consult recent literature and product documentation before designing new experiments.